Key result
Ischaemia-modified albumin plus hsTnT boosts 30-day major cardiovascular events sensitivity to ~90% versus troponin alone.
Why the study?
Does adding serum ischaemia-modified albumin (IMA ≥75 KU/litre) to initial highly sensitive cardiac troponin T (hsTnT) improve sensitivity for predicting 30-day major adverse cardiac events in emergency department patients with acute chest pain?
Cohort (n=322)
Collaborators running the IMA assay were blinded to the study hypothesis; treating doctors were blinded to IMA results
Yes
Does adding serum ischaemia-modified albumin (IMA ≥75 KU/litre) to initial highly sensitive cardiac troponin T (hsTnT) improve sensitivity for predicting 30-day major adverse cardiac events in emergency department patients with acute chest pain?
A serum IMA cutpoint of 75 KU/litre alone and combined with initial hsTnT significantly improves sensitivity for predicting 30-day MACE over initial hsTnT alone in ED chest pain patients, though specificity remains low.
Answers are grounded in this paper and cite their sources.
May aid 30-day MACE prediction in ED chest pain; hypothesis-generating and should not change practice without prospective trials.
OBJECTIVES: In patients with acute chest pain, we derived a cutpoint for ischaemia-modified albumin (IMA) and prospectively validated this cutpoint to predict 30-day major adverse cardiac events (MACEs). METHODS: We prospectively recruited a derivation cohort (18-month period) to establish a serum IMA cutpoint targeting 80% sensitivity. This was followed by a prospective validation cohort study of emergency department patients with acute chest pain at two university hospitals over a 3-month period. A MACE was defined as myocardial infarction, revascularisation or death at 30-day follow-up. RESULTS: In the derivation cohort of 151 patients, the IMA cutpoint that achieved 80% sensitivity for MACEs was 75 KU/litre. The sensitivity was prospectively validated in 171 patients consecutively enrolled, of whom 106 underwent multiple-biomarker analysis (19.8% MACE rate, 81% sensitivity of IMA). Furthermore, IMA by itself (81%, p<0.01) and in combination with initial highly sensitive cardiac troponin T (hsTnT) (90%, p<0.001) had significantly higher sensitivity than initial hsTnT (29%) for prediction of MACEs. CONCLUSIONS: We prospectively validated the sensitive IMA cutpoint of 75 KU/litre with 80% sensitivity for MACEs in patients with acute chest pain. Our data suggest that IMA alone and in combination with initial hsTnT are more sensitive than the initial hsTnT for MACEs.
No takes yet. Share an insight, caveat, or question.
Manini et al. (2009) conducted a cohort in Acute chest pain (n=322). Serum ischaemia-modified albumin (IMA) ≥75 KU/litre (alone and combined with initial hsTnT) vs. Initial highly sensitive cardiac troponin T (hsTnT) alone was evaluated on Sensitivity for 30-day major adverse cardiac events (MACE: myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, or all-cause mortality) (OR 2.4, 95% CI 0.8-7.9, p=<0.01). Ischaemia-modified albumin (≥75 KU/L) achieved 81% sensitivity alone and 90% sensitivity when combined with initial hsTnT, compared with 29% for initial hsTnT alone for 30-day major cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: